Human Tissue Authority

The regulator for human tissue and organs

HTA Strategy 2020-23

Introduction from the HTA’s Chair 

I am pleased to introduce the Human Tissue Authority’s Strategy for the period 2020-23.

Since taking up the role as the HTA’s Chair in November 2019, our operating environment has fundamentally changed as the UK responds to the COVID-19 pandemic. It has been a challenging time for everyone and, like others, we shall have a great deal to learn from the experience of regulating remotely and maintaining our focus on risk based and proportionate regulation.  We are pleased to have played our part in ensuring the public can continue to have confidence that patient safety is at the heart of what we do.

Although this is a period of significant change and uncertainty, the HTA’s role remains vital. Our guiding principles, values and strategic aims are central to what we aim to achieve.

Our Strategy continues to focus on the three key themes of sustainability, resilience, and agility.

In the period covered by this Strategy, we will continue to:

  • license and inspect establishments, in order to monitor compliance with legislation and best practice and take action where it is required. We will do this in an agile way, recognising that ways of working have changed and that different risks will have emerged;
  • provide advice and guidance to the public and professionals with an interest in the areas we work in and involve them in our work where appropriate;
  • work closely with our key partners across the system in order to ensure a consistent and joined up approach to healthcare regulation nationally;
  • ensure that we maintain public confidence in the systems we regulate, through an open and transparent approach to reporting and acting in an effective manner on any serious failures uncovered or concerns held.

To support this, we will continue with our programme of improvement examining how we can most effectively deliver our services in the future. This work will address, amongst other things, how we can better ensure that we: use our intelligence and knowledge of risk to support our inspection programme and inform our proportionate regulatory approach; engage with and involve the public and professionals through as wide variety of channels as possible and seek out new and useful ways to build and strengthen relationships with others.

The UK is extraordinarily well placed to play a leading role in the growth of the life sciences sector, with strengths in innovation, research, healthcare and business. 

The HTA is not alone in the regulatory environment in wanting to make the UK a great place for research and innovation to thrive, whilst ensuring patient safety is not compromised.

We anticipate that the next few years will be a challenging period, but with this challenge will come opportunities. As a regulator of six diverse sectors, we will play our part in building an effective regulatory environment that supports innovative, emerging technology and that can adapt to new and emerging risks.

I look forward to working with you to achieve these goals.

Last updated on: 11 Nov 2020